Influx Health.

How has been the historical performance of Influx Health.?

Influx Health showed positive financial performance from March 2024 to March 2025, with net sales increasing from 99.97 Cr to 104.85 Cr, operating profit rising from 16.96 Cr to 20.56 Cr, and profit after tax growing from 11.13 Cr to 13.37 Cr, despite a decrease in cash flow from operating activities. Total assets and liabilities both grew significantly, indicating balanced growth.

Answer:<BR>The historical performance of Influx Health shows a positive trend in key financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Influx Health's net sales increased from 99.97 Cr in March 2024 to 104.85 Cr in March 2025, reflecting a growth in total operating income from 99.97 Cr to 104.85 Cr. The raw material cost decreased slightly from 65.27 Cr to 63.41 Cr, while employee costs rose from 7.04 Cr to 8.79 Cr. Total expenditure, excluding depreciation, increased from 83.01 Cr to 84.29 Cr. Operating profit (PBDIT) rose from 16.96 Cr to 20.56 Cr, leading to an operating profit margin improvement from 16.97% to 19.61%. Profit before tax also increased from 14.93 Cr to 17.88 Cr, with profit after tax rising from 11.13 Cr to 13.37 Cr, resulting in a PAT margin increase from 11.13% to 12.75%. The company's total assets grew significantly from 40.82 Cr to 70.12 Cr, while total liabilities increased from 40.82 Cr to 70.12 Cr, indicating a balanced growth in both assets and liabilities. Cash flow from operating activities decreased from 8.00 Cr to 7.00 Cr, contributing to a net cash outflow of 1.00 Cr in March 2025, compared to no outflow in the previous year. Overall, Influx Health demonstrated a strong performance with improvements in profitability and asset growth.

Is Influx Health. overvalued or undervalued?

As of December 3, 2025, Influx Health is fairly valued with a PE ratio of 40.22, an EV to EBITDA of 24.18, and a ROCE of 33.05%, positioning it between peers Sun Pharma and Divi's Lab in terms of valuation.

As of 3 December 2025, Influx Health has moved from an attractive to a fair valuation grade. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 40.22, an EV to EBITDA of 24.18, and a ROCE of 33.05%. <BR><BR>In comparison to peers, Influx Health's PE ratio is higher than Sun Pharma's 37.51 and significantly lower than Divi's Lab's 68.92, which is categorized as very expensive. While the company has shown strong returns over the past week and month, outperforming the Sensex, its current valuation suggests that it is neither undervalued nor overvalued in the current market context.

Why is Influx Healthtech Ltd falling/rising?

As of 05-May, Influx Healthtech Ltd's stock price is at 276.25, down 1.48%, but has increased 10.21% over the past week and 28.31% over the past month, outperforming the Sensex. Despite today's decline and underperformance in its sector, the stock shows a positive long-term trend with significant investor interest.

As of 05-May, Influx Healthtech Ltd's stock price is currently at 276.25, reflecting a decrease of 4.15 (-1.48%). Despite this decline, the stock has shown strong performance over various periods, with a notable increase of 10.21% over the past week and 28.31% over the past month, significantly outperforming the Sensex, which has only risen by 0.15% and 5.81% respectively in the same time frames. Year-to-date, the stock has increased by 22.18%, while the Sensex has decreased by 8.02%.<BR><BR>Today's performance indicates that the stock is trading higher than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a generally upward trend in the stock's price over the longer term. Additionally, there has been a significant rise in investor participation, with delivery volume on May 4 increasing by 150% compared to the 5-day average, indicating growing interest among investors.<BR><BR>However, the stock has underperformed its sector today by 1.85%, which may contribute to the current decline in price. Furthermore, it is close to its 52-week high, being only 4.98% away from the high of Rs 290, which could also influence short-term trading behavior. Overall, while the stock is experiencing a slight decline today, its recent performance and investor interest suggest a generally positive outlook in the longer term.

Which are the latest news on Influx Health.?